Drugs / Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03167203 | Jan 2018 → Mar 2029 expected | macular degeneration | Astellas Institute for Regenerative Medicine | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03167203 ↗ |
| Modality | Cell therapy | “Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy” NCT03167203 ↗ |
| Route | Other | “sub-retinal transplant of hESC-RPE cells” NCT03167203 ↗ |